

Keystone Symposia 2017 Conference Series

Cell Plasticity within the Tumor Microenvironment (A1)

January 8–12, 2017 | Big Sky, Montana | USA

Precision Genome Engineering (A2)

Jan 8–12, 2017 | Breckenridge, Colorado | USA

Transcriptional & Epigenetic Control in Stem Cells (J1)

joint with Neurogenesis during Development & in the Adult Brain (J2)

Jan 8–12, 2017 | Olympic Valley, California | USA

TGF- β in Immunity, Inflammation & Cancer (A3)

January 9–13, 2017 | Taos, New Mexico | USA

Mitochondria Communication (A4)

January 14–18, 2017 | Taos, New Mexico | USA

New Developments in Our Basic Understanding of Tuberculosis (A5)

January 14–18, 2017 | Vancouver, British Columbia | Canada

PI3K Pathways in Immunology, Growth Disorders & Cancer (A6)

Jan 19–23, 2017 | Santa Fe, New Mexico | USA

Biobetters & Next-Generation Biologics:

Innovative Strategies for Optimally Effective Therapies (A7)

Jan 22–26, 2017 | Snowbird, Utah | USA

Diabetes (J3) *joint with Obesity & Adipose Tissue Biology (J4)*

January 22–26, 2017 | Keystone, Colorado | USA

Omics Strategies to Study the Proteome (A8)

January 29–February 2, 2017 | Breckenridge, Colorado | USA

Epigenetics & Human Disease:

Progress from Mechanisms to Therapeutics (A9)

January 29–February 2, 2017 | Seattle, Washington | USA

Hematopoiesis (B1)

January 31–February 4, 2017 | Banff, Alberta | Canada

Noncoding RNAs: From Disease to Targeted Therapeutics (J5)

joint with Protein-RNA Interactions: Scale, Mechanisms, Structure & Function of Coding & Noncoding RNPs (J6)

February 5–9, 2017 | Banff, Alberta | Canada

Inflammation-Driven Cancer: Mechanisms to Therapy (J7)

joint with Microbiome in Health & Disease (J8)

February 5–9, 2017 | Keystone, Colorado | USA

Autophagy Network Integration in Health & Disease (B2)

February 12–16, 2017 | Copper Mountain, Colorado | USA

Asthma: From Pathway Biology to Precision Therapeutics (B3)

February 12–16, 2017 | Keystone, Colorado | USA

Viral Immunity: Mechanisms & Consequences (B4)

February 19–23, 2017 | Santa Fe, New Mexico | USA

Malaria: From Innovation to Eradication (B5)

February 19–23, 2017 | Kampala | Uganda

Lipidomics & Bioactive Lipids in Metabolism & Disease (B6)

February 26–March 2, 2017 | Tahoe City, California | USA

Bile Acid Receptors as Signal Integrators in Liver & Metabolism (C1)

March 3–7, 2017 | Monterey, California | USA

Rare & Undiagnosed Diseases:

Discovery & Models of Precision Therapy (C2)

March 5–8, 2017 | Boston, Massachusetts | USA

mRNA Processing & Human Disease (C3)

March 5–8, 2017 | Taos, New Mexico | USA

Synapses & Circuits: Formation, Function & Dysfunction (X1)

joint with Connectomics (X2)

March 5–8, 2017 | Santa Fe, New Mexico | US

Tumor Metabolism: Mechanisms & Targets (X3)

joint with Adaptations to Hypoxia in Physiology & Disease (X4)

March 5–9, 2017 | Whistler, British Columbia | Canada

Engineered Cells & Tissues as Platforms for Discovery & Therapy (K1)

March 9–12, 2017 | Boston, Massachusetts | USA

Kinases: Next-Generation Insights & Approaches (C4)

March 5–9, 2017 | Breckenridge, Colorado | USA

Frontiers of NMR in Life Sciences (C5)

March 12–16, 2017 | Keystone, Colorado | USA

Sex & Gender Factors Affecting Metabolic Homeostasis, Diabetes & Obesity (C6)

March 19–22, 2017 | Tahoe City, California | USA

Cancer Immunology & Immunotherapy:

Taking a Place in Mainstream Oncology (C7)

March 19–23, 2017 | Whistler, British Columbia | Canada

Pattern Recognition Signaling: From Innate Immunity to Inflammatory Disease (X5) *joint with Type I Interferon: Friend & Foe Alike (X6)*

March 19–23, 2017 | Banff, Alberta | Canada

Injury, Inflammation & Fibrosis (C8)

March 26–30, 2017 | Snowbird, Utah | USA

HIV Vaccines (C9)

March 26–30, 2017 | Steamboat Springs, Colorado | USA

Immune Regulation in Autoimmunity & Cancer (D1)

March 26–30, 2017 | Whistler, British Columbia | Canada

Molecular Mechanisms of Heart Development (X7)

joint with RNA-Based Approaches in Cardiovascular Disease (X8)

March 26–30, 2017 | Keystone, Colorado | USA

Genomic Instability & DNA Repair (Z1)

joint with DNA Replication & Recombination (Z2)

April 2–6, 2017 | Santa Fe, New Mexico | USA

B Cells & T Follicular Helper Cells: Controlling Long-Lived Immunity (D2)

April 23–27, 2017 | Whistler, British Columbia | Canada

Mononuclear Phagocytes in Health, Immune Defense & Disease (D3)

April 30–May 4, 2017 | Austin, Texas | USA

Modeling Viral Infections & Immunity (E1)

May 1–4, 2017 | Estes Park, Colorado | USA

Angiogenesis & Vascular Disease (Z3)

joint with Mitochondria, Metabolism & Heart (Z4)

May 8–12, 2017 | Santa Fe, New Mexico | USA

Neuronal Control of Appetite, Metabolism & Weight (Z5)

joint with Gastrointestinal Control of Metabolism (Z6)

May 9–13, 2017 | Copenhagen | Denmark

Aging & Mechanisms of Aging-Related Disease (E2)

May 15–19, 2017 | Yokohama | Japan

Single Cell Omics (E3)

May 26–30, 2017 | Stockholm | Sweden

Integrating Metabolism & Immunity (E4)

joint with Cell Death & Inflammation (K2)

May 29–June 2, 2017 | Dublin | Ireland

Vectors, Pathogens & Diseases: Current Trends & Emerging Challenges (T1)

September 10–14, 2017 | Durban, KwaZulu-Natal | South Africa

Maternal-Fetal Cross Talk: Harmony vs. Conflict (T2)

October 4–8, 2017 | Washington, DC | USA

Regenerative Biology & Applications: Cell Differentiation, Tissue Organization & Biomedical Engineering (T3)

October 15–19, 2017 | Pok Fu Lam, Hong Kong | China

Antimicrobials and Resistance: Opportunities and Challenges (T4)

October 29–November 1, 2017 | Santa Fe, New Mexico | USA

Frontiers of Serotonin Beyond the Brain (T5)

November 12–15, 2017 | Park City, Utah | USA

Abstract and discounted registration deadlines are three months and two months, respectively, before conferences begin. Abstracts submitted by the abstract deadline will be considered for short talks on the program. Information shown subject to possible change.

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery